Ashtari Fereshteh, Toghianifar Nafiseh, Zarkesh-Esfahani Sayyed Hamid, Mansourian Marjan
a Department of Neurology , Isfahan University of Medical sciences , Isfahan , Iran.
b Isfahan Neuroscience Research Center , Isfahan University of Medical Sciences , Isfahan , Iran.
Neurol Res. 2016 Oct;38(10):888-92. doi: 10.1080/01616412.2016.1227913. Epub 2016 Sep 6.
Low level of vitamin D is associated with a more severe course and low quality of life in relapsing-remitting multiple sclerosis (RRMS). Low dose vitamin D intake has improved quality of life in RRMS patients.
This study explored the effect of high dose vitamin D intake on quality of life in RRMS patients in a double blind randomized clinical trial.
94 RRMS patients were randomized to two groups. One group received 50,000 IU vitamin D3 every five days for 3 months. The other group received placebo. Interferon-β (IFN-β) continued as the main treatment in both groups. Quality of life was assessed using MSQOL-54 Persian version at the beginning and at the end of the study.
After 3 months, the vitamin D group had a significant difference in mental health composite with placebo group, 62.41 ± 13.99 vs. 60.99 ± 17.99 (p-value = 0.041). Change in health was 75.74 ± 25.73 and 70.59 ± 26.45 in vitamin D and placebo group, respectively (p-value = 0.036).
Mental QOL improved significantly after taking high dose vitamin D for 3 months in vitamin D group relative to placebo.
维生素D水平低与复发缓解型多发性硬化症（RRMS）病程更严重及生活质量低相关。低剂量维生素D摄入可改善RRMS患者的生活质量。
本研究在一项双盲随机临床试验中探讨高剂量维生素D摄入对RRMS患者生活质量的影响。
94例RRMS患者随机分为两组。一组每五天接受50,000国际单位维生素D3，共3个月。另一组接受安慰剂。两组均继续以干扰素-β（IFN-β）作为主要治疗。在研究开始和结束时使用MSQOL-54波斯语版本评估生活质量。
3个月后，维生素D组与安慰剂组在心理健康综合评分上有显著差异，分别为62.41±13.99和60.99±17.99（p值=0.041）。维生素D组和安慰剂组的健康变化分别为75.74±25.73和70.59±26.45（p值=0.036）。
与安慰剂相比，维生素D组在服用高剂量维生素D 3个月后，心理生活质量显著改善。
